Effects of Cilostazol on Patients Undergoing Intervention for Chronic Limb-threatening Ischemia

The benefits of cilostazol on claudicant patients with prior aortoiliac or femoropopliteal revascularization is previously described, but the literature preoperative use this medication in chronic limb-threatening ischemia (CLTI) limited. We hypothesized that undergoing intervention for CLTI would have reduced perioperative amputations, and improved long-term survival. Vascular Quality Initiative (5/2012 to 10/2021) who underwent aortoiliac/femoropopliteal revascularizations were included. Patients grouped as either no cilostazol, all heart failure excluded. Incomplete covariate information was imputed. groups matched 1:1 clinical demographic characteristics. primary end point all-cause mortality. Our secondary amputation. There 1615 taking 23,232 not included final analysis. 10,274 presented ischemic rest pain, 13,805 tissue loss, 596 nonhealing amputation sites, 172 ulceration amputation, equal across groups. 8131 interventions 16,716 statistically significant differences targets between Stand-alone superficial femoral artery most common both unmatched cohorts (matched 883, 27.3%; 7748, 31.2%), standalone least commonly performed procedure 56, 1.7%; 327, 1.3%). group had a significantly lower incidence weighted (3.4% vs 5.1%; P < .05) adjusted analysis (odds ratio, 0.7; 95% confidence interval, 0.5-0.9; .05). Similarly, associated higher 6-year survival (85% 76% cilostazol; hazard 0.5; 0.4-0.8; .001) (Figure). Pretreatment angioplasty stenting In CTLI, therapy before extremity peripheral may help reduce risk improve Future studies address limb salvage prolonged postoperative period patient outcomes after various procedures, including stenting.